Monaco
@monaco_biotech
#biotech investor since 1998. Also tech/SPAC investor. I trade longterm, swing, day. My posts are not investment advice.
If you wish rate cuts for your stocks then you are in the wrong stocks. It's as simple as that.
$SRPT Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union - SRPT • BioPharmCatalyst biopharmcatalyst.com/company/SRPT/n…
$SRPT Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS - SRPT • BioPharmCatalyst biopharmcatalyst.com/company/SRPT/n…
Super interesting lies in this tweet. Be careful not to get scammed by made up shit like this, folks. $VKTX
$VKTX was undervalued at $85 and CEO Brian Lian reportedly rejected multiple premium buyout offers; even after hedge fund pressure pushed the stock toward $20 he has not wavered. He now indicates bidding must start around $43 B ($385 per share, the price Pfizer paid for Seagen…
$SRPT FDA Investigating Death of 8-Year-Old Boy Who Received Elevidys. fda.gov/news-events/pr…
If having to talk yourself into staying in a position, a clear 🚩 (sunk cost)
BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Fall 2025 $ZYNE $ENTA $RLYB $KALA $ASMB $CAPR $RPTX $ASMB $XCUR biopharmcatalyst.com/news/2025/key-…
Biotech Idea of the Day: $Atyr Pharma. I thought it might be apropos to ramble on one more time about Atyr on the eve of the penultimate phase 3 readout (sometime in Q3). This is lengthy so to summarize for those without long attention spans I’m still leaning bullish, especially…
$CELC New to the story but all I can say is we need to stop complaining about P3 failures when we decide to fund a 700-patient pivotal trial based on a 27-patient open label combo arm (esp when a similar cohort with a slightly different schedule does not look as promising)🙄
$CELC Monday, July 28, 2025 at 8:00 AM ET 📌 Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial i... - CELC • BioPharmCatalyst biopharmcatalyst.com/company/CELC/n…
$ATAI -20% 📉 AH #fail Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive... - ATAI • BioPharmCatalyst biopharmcatalyst.com/company/ATAI/n…
$ASPI Competition Commission of South Africa Approves the Offer by ASP Isotopes Inc. for Renergen Limited - ASPI • BioPharmCatalyst @EricTheUmpire biopharmcatalyst.com/company/ASPI/n…
$ABSI (-16.2% pre) Absci Announces Pricing of Public Offering of Common Stock ooc.bz/l/71259
$IMVT (-4.8% pre) IMVT Hearing 3M share block secondary priced at $17.85 - Source TradeTheNews.com ooc.bz/l/71263
Powell privately adamant that he will serve out his full term at the Fed - CNN
$LYEL +12% 📈 pre-market Lyell Immunopharma Announces up to $100 Million Equity Private Placement - LYEL • BioPharmCatalyst biopharmcatalyst.com/company/LYEL/n…
$MDGL Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets 📌 Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August... - MDGL • BioPharmCatalyst biopharmcatalyst.com/company/MDGL/n…
$PHIO +35% 📈 pre-market Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance - PHIO • BioPharmCatalyst biopharmcatalyst.com/company/PHIO/n…
$JANX resurrects a TROP2 asset, and continues tinkering with CD28. Meanwhile, JANX007 & JANX008 data are a waiting game. Via @ApexOnco -> oncologypipeline.com/apexonco/node/… $CTMX
$RHHBY $SRPT Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU - RHHBY • BioPharmCatalyst biopharmcatalyst.com/company/RHHBY/…